Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRL | P40313 | 7/20 | 0.58 |
| ▸ | TMPRSS11D | O60235 | 5/20 | 0.58 |
| ▸ | PSMB5 | P28074 | 11/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.57 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.57 |
| ▸ | CYP3A43 | Q9HB55 | 2/20 | 0.57 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.57 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.57 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.57 |
| ▸ | PSMD12 | O00232 | 1/20 | 0.57 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.57 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.57 |
| ▸ | PSMD3 | O43242 | 1/20 | 0.57 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | PSMC3 | P17980 | 1/20 | 0.57 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.57 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.57 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.57 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17750788 | 1.00 | CTRL (0.58) | CTRLTMPRSS11DPSMB5CYP3A4CYP3A5 | |
| SCHEMBL16254118 | 0.90 | CTRL (0.59) | CTRLTMPRSS11DPSMB5CYP3A4CYP3A5 | |
| SCHEMBL8266994 | 0.90 | CTRL (0.71) | CTRLTMPRSS11DPSMB5CYP3A4CYP3A5 | |
| SCHEMBL20284864 | 0.90 | CTRL (0.71) | CTRLTMPRSS11DPSMB5CYP3A4CYP3A5 | |
| SCHEMBL20000632 | 0.90 | CTRL (0.71) | CTRLTMPRSS11DPSMB5CYP3A4CYP3A5 | |
| SCHEMBL8267559 | 0.90 | CTRL (0.64) | CTRLTMPRSS11DPSMB5CYP3A4CYP3A5 | |
| SCHEMBL16104625 | 0.90 | CTRL (0.64) | CTRLTMPRSS11DPSMB5CYP3A4CYP3A5 | |
| SCHEMBL21793849 | 0.85 | CTRL (0.57) | CTRLTMPRSS11DPSMB5CYP3A4CYP3A5 | |
| SCHEMBL84994 | 0.85 | PSMB5 (0.68) | CTRLTMPRSS11DPSMB5CYP3A4CYP3A5 | |
| SCHEMBL22545161 | 0.84 | CTRL (0.56) | CTRLTMPRSS11DPSMB5CYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179663-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX, INC. | 2021-06-17 | — | — | US | disclosed |
| US-20200325172-A1 | Compounds for proteasome enzyme inhibition | PROTEOLIX, INC. | 2020-10-15 | — | — | US | disclosed |
| US-20190211058-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20180170962-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20160222057-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2016-08-04 | — | — | US | disclosed |
| US-8198270-B2 | Compounds for proteasome enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20090131421-A1 | Compounds for proteasome enzyme inhibition | ONYX THERAPEUTICS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-7417042-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| WO-2006017842-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030533-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222057-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | CTRL 43/4885TMPRSS11D 338/4885PSMB5 14/4885 |
| US-20180170962-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | CTRL 43/4885TMPRSS11D 338/4885PSMB5 14/4885 |
| US-20200325172-A1 | Compounds for proteasome enzyme inhibition | PSMB1, PSMB9, PSMB3 | CTRL 43/4885TMPRSS11D 338/4885PSMB5 14/4885 |
| US-20190211058-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | CTRL 43/4885TMPRSS11D 338/4885PSMB5 14/4885 |
| US-20090131421-A1 | Compounds for proteasome enzyme inhibition | PSMB1, PSMB9, PSMB3 | CTRL 43/4885TMPRSS11D 338/4885PSMB5 14/4885 |
| US-20210179663-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | CTRL 43/4885TMPRSS11D 338/4885PSMB5 14/4885 |
| US-20060030533-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | CTRL 10/4885TMPRSS11D 386/4885PSMB5 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.